Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2015 Aug 21;5:13041. doi: 10.1038/srep13041

Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model

Yu Seri 1, Hirofumi Shoda 1, Akari Suzuki 2, Isao Matsumoto 3, Takayuki Sumida 3, Keishi Fujio 1,a, Kazuhiko Yamamoto 1,2
PMCID: PMC4544002  PMID: 26293116

Abstract

Peptidyl arginine deiminase 4 (PAD4) is an enzyme that is involved in protein citrullination, and is a target for anti-citrullinated peptide antibodies (ACPAs) in rheumatoid arthritis (RA). Genetic polymorphisms in the PADI4 gene encoding PAD4 are associated with RA susceptibility. We herein analyzed the roles of PADI4 in inflammatory arthritis using a glucose-6-phosphate isomerase (GPI)-induced arthritis (GIA) model in Padi4 knockout (KO) mice. Arthritis severity, serum anti-GPI antibody titers, and IL-6 concentrations were significantly reduced in Padi4 KO mice. The frequency of Th17 cells was decreased in GPI-immunized Padi4 KO mice, whereas WT and Padi4-deficient naïve CD4+ T cells displayed the same efficiencies for Th17 cell differentiation in vitro. In addition, the numbers of myeloid lineage cells were reduced with the increased expression of pro-apoptotic genes in GPI-immunized Padi4 KO mice. Furthermore, the survival of Padi4-deficient neutrophils was impaired in vitro. Our results suggest that PADI4 exacerbates arthritis with diverse immunological modifications.

Rheumatoid arthritis (RA) is characterized by sustained and destructive polyarthritis with an autoimmune background. Environmental and genetic factors have both been shown to contribute to the pathogenesis of RA; however, its pathogenesis has not yet been elucidated in detail1,2. A recent genome-wide associated study (GWAS) provided a larger amount of genetic information on RA3. Peptidylarginine deiminase type 4 (PADI4) was the initially identified genetic susceptibility locus of RA in the non-major histocompatibility molecule (MHC) locus4. Furthermore, although most of the recently identified autoimmunity loci are shared among multiple autoimmune diseases, PADI4 is uniquely associated with RA5, which suggests the principle importance of PADI4 in the pathogenesis of RA.

PADI genes encode PAD proteins that convert arginine residues to citrulline in the presence of sufficient Ca2+ concentrations6, and protein citrullination is one of the post-translational modifications that have been reported. PADI4 possesses some distinctive characteristics from the four other human PADI isotypes. It is mainly expressed in myeloid lineage cells, such as neutrophils and monocytes, and its expression is inducible under inflammatory conditions6,7. PADI4 has nuclear localization signals that permit its translocation to the nucleus8. The RA-susceptible PADI4 haplotype has been shown to give rise to more stable PADI4 mRNA and is associated with increases in PAD4 protein levels4. These findings suggest that the enhanced and uncontrolled production of citrullinated antigens results in the development of an anti-citrullinated peptide antibody (ACPA) and the occurrence of joint inflammation in patients with the RA-susceptible PADI4 haplotype. However, two recent reports demonstrated that PADI4 is associated with ACPA-negative RA patients in Asian populations and one of the risk factors for bone destruction independent of ACPA status9,10. These findings suggest an ACPA-independent pathway for the association of PADI4 with the pathogenesis of RA. Previous studies in which the homeostatic activities of PADI4, such as transcriptional modulation, cell cycle/apoptosis regulation, and the acquirement for pluripotency, were demonstrated to support this possibility11,12,13,14,15,16,17.

Recombinant human glucose-6-phosphate isomerase (rhGPI)-induced arthritis (GIA) is an established and immunologically characterized model of RA18. The development and exacerbation of GIA has been shown to depend on CD4+ T cells, especially Th17 cells and IL-618,19. Therefore, GIA is a suitable model not only for examining arthritis, but also evaluating various immunological events that occur during the course of arthritis. We herein tested the GIA model in Padi4 KO mice and demonstrated a reduction in joint inflammation. We observed decreases in the number of Th17 cells, levels of serum anti-GPI antibodies and IL-6, and the number of myeloid lineage cells in GPI-immunized Padi4 KO mice. Furthermore, the survival of Padi4-deficient neutrophils was impaired in vitro. Taken together, Padi4 exacerbated RA with diverse immunological modifications.

Results

Reduced severity of GIA in Padi4 KO mice

WT and Padi4 KO mice both developed arthritis approximately 7 days after the rhGPI immunization and arthritis scores increased between 8 and 14 days after the immunization. Most of the immunized WT and Padi4 KO mice developed arthritis, and no significant difference was observed in the incidence of arthritis (Fig. 1A). Arthritis severity scores were significantly lower in Padi4 KO mice than in WT mice (Fig. 1B). The histological scores for inflamed joints were also lower in Padi4 KO mice than in WT mice (Fig. 1C,D). These results demonstrated that Padi4 was associated with the exacerbation of GIA.

Figure 1. Comparative analyses of wild-type (WT) and Padi4 knock out (KO) mice of recombinant human Glucose-6-phosphate isomerase (rhGPI)-induced arthritis (GIA).

Figure 1

Open in a new tab

(A) The incidence of GIA. (B) The mean severity of GIA graded by previously reported methods. (WT n = 11, Padi4 KO n = 13) (C,D) Representative arthritic joint sections and mean histological scores were graded by previously reported methods 14 days after the immunization. ¶: inflammatory cell infiltration, §: cartilage destruction, †: bone erosion. Gray bars; WT, open bars; Padi4 KO. (E,F) The numbers of splenocytes and inguinal lymph node cells were counted 0, 7, and 14 days after the immunization. Pre-immunized (WT n = 3, Padi4 KO n = 3), 7 days after the immunization (WT n = 9, Padi4 KO n = 9), 14 days after the immunization (WT n = 14, Padi4 KO n = 16). *p < 0.05.

We initially focused on the number of immune cells in lymphoid organs in the pre-arthritic phase (7 days after the immunization) and arthritic phase (14 days after the immunization). In the pre-arthritic phase, the increased number of whole splenocytes in number was attenuated more in Padi4 KO mice than in WT mice (Fig. 1E). In the arthritic phase, the numbers of splenocytes and iLN cells were both lower in Padi4 KO mice than in WT mice (Fig. 1E,F). These results suggested that the pre-arthritic immune responses in Padi4 KO and WT mice differed.

Lower serum anti-GPI antibody titers in Padi4 KO GIA mice

We then examined B cell subsets and anti-GPI antibody production following the rhGPI immunization because B cells and the anti-GPI antibody were required for the development of GIA18,20. After the rhGPI immunization, no significant difference was observed in the total number of B cells in the spleen or iLN cells between WT and Padi4 KO mice (Fig. 2A). Regarding serum antibodies, although rhGPI-immunized WT mice developed significant amounts of anti-GPI IgM and IgG antibodies, Padi4 KO mice only produced limited titers of anti-GPI IgM and IgG antibodies (Fig. 2B,C). Moreover, ACPA titers after rhGPI immunization were lower in Padi4 KO mice (Fig. 2D).

Figure 2. B cells and serum anti-GPI antibodies in Padi4 KO mice after the GPI immunization.

Figure 2

Open in a new tab

(A) The number of B220+ B cells in spleens was counted 0, 7, and 14 days after the immunization. Pre-immunized (WT n = 3, Padi4 KO n = 3), 7 days after the immunization (WT n = 6, Padi4 KO n = 6), 14 days after the immunization (WT n = 11, Padi4 KO n = 13). (B–D) The titers of serum anti-GPI IgM, IgG antibodies and anti-CCP2 IgG antibodies were measured before and 14 days after the immunization. Pre-immunized (WT n = 3, Padi4 KO n = 3), 14 days after the immunization (WT n = 13, Padi4 KO n = 13), N.D.: not detected. *p < 0.05.

Decreased number of Th17 cells in Padi4 KO GIA mice

CD4+ T cells, especially Th17 cells, play a pivotal role in the development of GIA21. In non-immunized DBA1 mice and GIA mice, the numbers of CD3+ T cells, CD62L− CD44+ CD4+ memory T cells, and CD62L− CD69+ CD4+ activated T cells in the spleens and iLNs were similar between Padi4 KO and WT mice (Fig. 3A–C), as was the number of CD25+ Foxp3+ CD4+ regulatory T cells (Fig. 3D). However, the frequency of iLN GPI-specific Th17 cells, but not Th1 cells, was significantly reduced in Padi4 KO mice either 7 or 14 days after the rhGPI immunization (Fig. 4A,B). On the other hand, no significant change was noted in the proliferation of CD4+ T cells, as analyzed by CFSE dilution, between WT and Padi4 KO mice (Fig. 4C).

Figure 3. T cell proliferation and activation in Padi4 KO mice after the GPI immunization.

Figure 3

Open in a new tab

(A–C) The numbers of CD3+ T cells, CD4+ CD62L− CD44+ memory T cells, and CD4+ CD62L− CD69+ activated T cells in spleens were counted 0, 7, and 14 days after the immunization. Pre-immunized (WT n = 3, Padi4 KO n = 3), 7 days after the immunization (WT n = 6, Padi4 KO n = 6), 14 days after the immunization (WT n = 11, Padi4 KO n = 13). (D) The number of CD4+ CD25+ Foxp3+ regulatory T cells in spleens was counted 14 days after the immunization (WT n = 8, Padi4 KO n = 10). Gray bars; WT, open bars; Padi4 KO.

Figure 4. Th17 cell differentiation in Padi4 KO mice after the GPI immunization.

Figure 4

Open in a new tab

(A,B) Proportions of Th1 and Th17 cells in the total amount of CD4+ T cells from inguinal lymph nodes 7 and 14 days after the immunization. Seven days after the immunization (WT n = 9, Padi4 KO n = 11), 14 days after the immunization (WT n = 6, Padi4 KO n = 6). (C) The CFSE dilution of CD4+ T cells from GPI-immunized inguinal lymph nodes was measured in response to an ex vivo stimulation with GPI (WT n = 3, Padi4 KO n = 3). (D) Proportion of in vitro differentiated Th17 cells in CD4+ T cells under Th17-polarizing conditions (WT n = 3, Padi4 KO n = 3). *p < 0.05, ***p < 0.001.

To determine whether the impairment observed in Th17 cell differentiation in Padi4-deficient mice was caused in a T cell intrinsic manner, naive WT or Padi4-deficient CD4+ T cells were cultured under Th17 cell-polarizing conditions. Padi4-deficient CD4+ T cells as well as WT CD4+ T cells efficiently differentiated into Th17 cells in vitro (Fig. 4D). These results suggested that the decreases observed in Th17 cells in Padi4 KO GIA mice were due to some extrinsic causes during the course of the rhGPI immunization rather than to intrinsic defects in Padi4-deficient CD4+ T cells.

Decreased serum IL-6 concentrations in Padi4 KO GIA mice

IL-6 is a key cytokine in the induction of Th17 cells, and is also important for joint inflammation. Serum IL-6 concentrations were already reduced in Padi4 KO mice in the pre-arthritic phase, and the evident reduction continued in the arthritic phase (Fig. 5A). A previous study reported that myeloid lineage cells were the main source of IL-6 in a GIA model19. Although we investigated the expression of IL-6 in the spleen in the pre-arthritic phase, a significant decrease was not observed in PADI4 KO mice (Fig. 5B).

Figure 5.

Figure 5

Open in a new tab

(A) Serum IL-6 concentrations in Padi4 KO mice 7 and 14 days after the GPI immunization. Serum IL-6 concentrations were measured by an enzyme-linked immunosorbent assay (WT n = 6, Padi4 KO n = 7). Gray dots; WT, open dots; Padi4 KO. Comparisons were performed using two-way analysis of variance followed by Bonferroni post-hoc test. *p < 0.05. (B) IL-6 gene expression levels in spleens were measured by quantitative PCR 7 days after the immunization (WT n = 3, Padi4 KO n = 3). Gray bars; WT, open bars; Padi4 KO.

Decreased numbers of CD11b + cells in Padi4 KO mice after the rhGPI immunization

Previous studies demonstrated that the Padi4 gene was mainly expressed in myeloid lineage cells6. In the case of the GIA model, Padi4 was dominantly expressed in CD11b+ Ly-6G+ neutrophils (Neus) and CD11b+ Ly-6C+ Ly-6G− monocytes (MCs), not T cells or B cells (Fig. 6A). As shown in Fig. 1D, although the total cell numbers of splenocytes and iLN cells were significantly decreased in Padi4 KO GIA mice, the number of B cells or T cells remained unchanged in Padi4 KO mice (Figs 2A and 3A). In contrast, the numbers of Neus and MCs were significantly decreased in the spleens of Padi4 KO mice 7 days after the rhGPI immunization (Fig. 6B). Furthermore, the expression of pro-apoptotic genes, such as Bid, Bad, and Bax, was increased in Padi4-deficient Neus and MCs from rhGPI-immunized mice (Fig. 6C,D). The expressions of these pro-apoptotic genes were not different in the lymphoid lineage cells (Fig. 6E,F). Moreover, the survival of PADI4-deficient Neus, not MCs, was impaired in the in vitro culture with or without the LPS stimulation (Fig. 7). These results suggested that PADI4 controls the survival of myeloid lineage cells.

Figure 6. Neutrophil and monocyte numbers after the GPI immunization.

Figure 6

Open in a new tab

(A) The expression of Padi4 in CD11+ Ly-6G+ neutrophils (Neus), CD11+ Ly-6C+ Ly-6G− monocytes (MCs), CD3+ T cells, and CD19+ B cells was measured by quantitative PCR 7 days after the immunization (WT = 3, Padi4 KO = 3). (B) The numbers of Neus and MCs in spleens were counted 7 days after the immunization (WT n = 9, Padi4 KO n = 9). (C–F) Pro-apoptotic gene expression in Neus, MCs, T cell, and B cells was measured by quantitative PCR 7 days after the immunization (WT n = 3, Padi4 KO n = 3). Gray bars; WT, open bars; Padi4 KO. *p < 0.05.

Figure 7. In vitro survival of Padi4-deficient neutrophils and monocytes.

Figure 7

Open in a new tab

(A,B) Splenic CD11+ Ly-6G+ neutrophils (Neus) and CD11+ Ly-6C+ Ly-6G− monocytes (MCs) were cultured with or without LPS and their survival was measured by FACS (WT n = 3, Padi4 KO n = 3). Gray bars; WT, open bars; Padi4 KO. *p < 0.05.

Discussion

In the present study, we demonstrated that the severity of arthritis was reduced in GPI-immunized Padi4 KO mice by various changes in immune reactions, including myeloid lineage cells, IL-6, antibodies and Th17 cells. Previous studies reported the effects of a deficiency in or the inhibition of Padi4 in inflammatory arthritis models. In the case of antibody-dependent arthritic models, Padi4 was dispensable for the arthritis effector phase. Administration of the Pan - PAD molecule inhibitor, Cl-amidine, did not reduce the severity of anti-type II collagen antibody-induced arthritis (CAIA)22. In the KxB/N serum transfer arthritis model, no significant differences were found in the severity of arthritis in Padi4 KO mice and WT mice23. On the other hand, in the type II collagen-induced arthritis (CIA) model, the administration of Cl-amidine reduced anti-type II collagen antibody production and the severity of arthritis22. Furthermore, Padi4 KO TNF alpha transgenic (Tg) mice had milder arthritis and less activated CD4+ T cells and some ACPAs than WT–TNF alpha Tg mice24. Therefore, the characteristics and roles of ACPAs in mouse models of arthritis are complicated, and will be elucidated, although serum ACPA development was significantly supressed in Padi4 KO GIA mice. Taken together, we demonstrated diverse immunological modifications, including helper T cell development, cytokine production, and immune cell apoptosis in Padi4 KO mice, which played certain roles in the pathogenesis of arthritis.

Previous studies demonstrated that antibody production was impaired under Padi4-deficient conditions22,24. GPI-immunized Padi4 KO mice had lower serum anti-GPI antibody titers than WT mice. However, in terms of arthritogenic potential, serum anti-GPI antibody titers did not correlate with the severity of arthritis in the GIA model18,20. Therefore, the reduction observed in arthritis severity in Padi4 KO mice may be explained by factors other than reductions in anti-GPI antibody levels. In previous studies on GIA models, IL-6, IL-17, and CD4+ T cells were identified as crucial components for the development and severity of GIA21. In Padi4 KO mice, serum IL-6 concentrations and the number of Th17 cells were significantly decreased. Therefore, there is a possibility that the decreased activation of the IL-6-Th17 axis, a direct arthritogenic cascade, reduced the severity of arthritis in the GIA models. However, it remains unclear whether the suppression of arthritis in Padi4 KO GIA was relevant to Th17 and/or Th1-mediated inflammatory process, and further investigations are required in this point. With regard to IL-6, high serum concentration was reported to be a characteristic finding and play a pivotal role in newly onset ACPA-positive RA patients25. In our experiment, GIA mice similarly exhibited serum IL-6 elevation in the early phase in a Padi4-dependent manner. Therefore, Padi4-mediated control of IL-6 may contribute to the early stage of RA. Furthermore, CD11b+ cells have been identified as one of the major IL-6 sources in mice models of RA19,26. Since a decrease in the number of CD11b+ cells was evident in GPI-immunized Padi4 KO mice, this shortage of IL-6 sources represents one possible explanation for the reduced arthritis severity in Padi4 KO mice. The dominant infiltrating cells were polymorphonuclear neutrophils (PMNs) in WT GIA mice (Fig. 1C). Enhanced apoptosis of Padi4-deficient neutrophils may explain the reduced cellular infiltration in the joints of Padi4 KO GIA mice. Otherwise, decreased numbers of Th17 cells could regulate the chemoattraction of the neutrophils to the joints, because Th17 cells were reported to secrete CXCL8, which was associated with neutrophil chemotaxis27.

Neutrophils strongly express Padi4 and play important roles not only in direct tissue injury, but also in the modulation of adaptive immune responses28. The expression of Padi4 was previously reported to be crucial for the formation of neutrophil extracellular traps (NETs)29,30,31,32. NETs contain citrullinated proteins, such as citrullinated histone, and are assumed to be a source of autoantigens. NETs also exhibit an adjuvant activity that activates dendritic cell (DC) function and T cell priming31,32,33,34,35,36. Apart from being a possible source of IL-6 in the GIA model, CD11b+ neutrophils play pivotal roles in the maturation of adaptive immune responses and GIA development via the production of NETs. Although the precise roles of NETs in mice arthritis models, including GIA, remain unclear, some reports suggested the importance of NETs in human RA33,34. Especially, Khandpur et al. reported that NETs induce IL-6 and IL-8 secretion from RA fibroblast-like synoviocytes (FLSs)34. Therefore, loss of NETs could be associated with the decrease of serum IL-6 in Padi4 KO GIA mice. Furthermore, the expression of Padi4 may control the survival and functions of neutrophils. More detailed information is needed about the nature of Padi4 in order to elucidate these points.

The molecular mechanisms of action of Padi4 in CD11b+ cells remain unknown. PAD4 was previously shown to be located in the nucleus, and regulated gene transcription through the citrullination of histones11,13. An analysis of the relationship between Padi4 and tumor cells has also provided some insights into this topic. Previous studies showed that PAD4 inhibited p53 and promoted cell proliferation by cancelling G1 arrest in the cell cycle17. PAD4 also displayed anti-apoptotic effects by suppressing several pro-apoptotic molecules14,15,16. Therefore, we speculated that nuclear molecular targets coupled with PAD4 can regulate gene transcription and cell survival.

In summary, we herein demonstrated reductions in the severities of GIA in Padi4 KO mice. Moreover, diverse modifications in the immune responses were observed in GPI-immunized Padi4 KO mice, such as decreases in serum IL-6 levels, Th17 cell development, and anti-GPI antibody production. Especially, the number of peripheral myeloid lineage cells was significantly decreased in GPI-immunized Padi4 KO mice, and the survival of Padi4-deficient neutrophils was impaired in vitro. Taken together, Padi4 exacerbate inflammatory arthritis with diverse immunological modifications which play certain roles in the pathogenesis of arthritis. Based on the reduction of the severities of arthritis in Padi4 KO mice, Padi4 suppression could be clinically adopted in human translational medicine.

Materials and Methods

Mice

Age- and Sex-matched DBA1J mice were supplied by SLC Japan (Shizuoka, Japan). Padi4 knockout (Padi4 KO) mice were generated by the deletion of exon 1 in the B6 background. The Padi4 KO B6 mice were backcrossed to the DBA/1J background for at least 17 generations to obtain Padi4 KO DBA1J mice with more than 99.5% identity with the original DBA1J mice37. The protocols used were approved by the Ethical Committee on Animal Experiments of the University of Tokyo, and all animal experiments were conducted in accordance with institutional and national guidelines.

GIA

rhGPI was generated and purified as described previously38. DBA/1J male mice were immunized with 300 μg of rhGPI plus an equal volume of Complete Freund’s adjuvant (DIFCO LABORATORIES, Detroit, MI, USA). Mice were sacrificed and blood, spleen, inguinal lymph nodes, and limbs were gathered 7 or 14 days after the immunization. In the histological analysis, joint sections were prepared and stained with hematoxylin and eosin by the Biopathology Institute Company (Oita, Japan). Synovial tissues were graded by inflammatory cell infiltration, cartilage destruction, and bone erosion as described previously39.

CD4 + T cell culture

Inguinal lymph node (iLN) cells (1 × 105/mL) were cultured with irradiated splenocytes (1 × 106/mL) with or without rhGPI (5 μg/mL) in RPMI 1640 medium supplemented with 5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 5 × 10−5 M 2-mercaptoethanol in a humidified incubator at 37 °C, 5% CO2, for 72 h. In some experiments, mouse CD4+ T cells were labeled with 1 × 10−6 M of carboxyfluorescein diacetate succinimidyl ester (CFSE) and then cultured on anti-CD3 antibody and anti-CD28 antibody-coated plates under Th17-inducing conditions38. To achieve intracellular cytokine staining, cells were stimulated with 1 × 10−5 M PMA and 0.5 μg/ml ionomycin and treated with Golgistop (BD Bioscience) 3 hours before being harvested.

Flow cytometry

Cell surface markers and intracellular cytokines were analyzed and cell sorting was performed by FACS Vantage (BD Bioscience). Endogenous Fc receptors were blocked using an anti-mouse CD16/CD32 antibody (2.4.G2; BD Bioscience) and subsequently stained using fluorescein isothiocyanate, phycoerythrin, allophycocyanin (APC), APC-Cy7, and the following biotin-conjugated antibodies. Anti-mouse Ly-6G (1A8), Ly-6C (AL21), CD25 (PC61), NK1.1 (PK136), CD3 (17A2), CD8a (53-6.7), IL-17A (TC11-18H10), and Annexin V antibodies were obtained from BD Bioscience. Anti-mouse F4/80 (BM8), CD4 (GK1.5), CD11c (N418), CD45R/B220 (RA3-6B2), CD62L (MEL-14), CD44 (IM7), and CD69 (H1.2F3) antibodies were obtained from Biolegend (San Diego, CA, USA). Anti-mouse CD11b (M1/70) and IFN-gamma (XMG1.2) antibodies were obtained from eBioscience (San Diego, CA, USA). APC-Cy7-conjugated streptavidin was obtained from Biolegend. Intracellular cytokine staining was performed with Fixation/Permeabilization Concentrate and Diluent (eBioscience) following the manufacturer’s protocol.

ELISA

Serum IL-6 concentrations were measured by Mouse IL-6 High Sensitivity ELISA according to the manufacturer’s protocol (eBioscience). Serum anti-GPI IgM and IgG antibodies were measured by ELISA according to a previously reported protocol with slight modifications39. A serum mixture of 4 WT mice 14 days after immunization was used as 1000 unit (U) standard of the anti-GPI antibody. Serum anti-CCP2 antibodies were measured by Mesacup CCP2 test (MBL) in accordance to the previous study40.

RNA extraction and quantitative PCR

RNA was extracted from cells using the RNeasy Micro Kit (Qiagen, Valencia, CA, USA). Extracted RNA was reverse-transcribed to cDNA with random primers (Invitrogen, Carlsbad, CA, USA) and Superscript III according to the manufacturer’s protocol (Invitrogen). Quantitative PCR was performed using the SYBR Green Master Mix (Qiagen) and iCycler system (Bio-rad, Hercules, CA, USA). The results obtained were shown in terms of relative expression levels compared to GAPDH. The primers used in quantitative PCR were listed in Supplementary Table.

In vitro survival assay

Isolated splenocytes from non-immunized mice were cultured in RPMI1640 medium supplemented with 5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 5 × 10−5 M 2-mercaptoethanol in the presence or absence of LPS (100 ng/mL) (Sigma) in a humidified incubator at 37 °C, 5% CO2, for 24 h. The percentages of Annexin V-negative CD11b+ Ly6G+ and Ly6C+ cells were analyzed by FACS.

Statistical analysis

Statistical analyses were performed by SPSS (IBM, Armonk, NY, USA). Data were expressed as the mean ± SEM. Differences were compared by the non-parametric test. Comparisons of more than three groups were performed using two-way analysis of variance followed by Bonferroni post-hoc test. P values less than 0.05 were considered significant.

Additional Information

How to cite this article: Seri, Y. et al. Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model. Sci. Rep. 5, 13041; doi: 10.1038/srep13041 (2015).

Supplementary Material

Supplementary Information
srep13041-s1.pdf (31.8KB, pdf)

Acknowledgments

The authors are grateful to Ms. Kanako Sakashita, Ms. Jun Takizawa, and Ms. Kayako Watada for their excellent technical assistance. This study was supported by a Grant - in - Aid for Scientific Research (S) (23229007) and Japan Society for the Promotion of Science. The part of this work was supported by grant form Santen Pharmaceutical.

Footnotes

Author Contributions S.Y. and H.S. designed, performed and analyzed the experiments in this study. A.S. generated the knockout mice. I.M. and T.S. provided GPI for arthritis models, and also provided advice. K.F. designed the study and provided advice. K.Y. provided overall coordination with respect to conception, design and supervision of the study. Y.S., H.S. and K.Y. wrote the manuscript with comments from co-authors.

References

  1. Scott D. L., Wolfe F. & Huizinga T. W. Rheumatoid arthritis. Lancet 376, 1094–1108 (2010). [DOI] [PubMed] [Google Scholar]
  2. McInnes I. B. & Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205–2219 (2011). [DOI] [PubMed] [Google Scholar]
  3. Okada Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Suzuki A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34, 395–402 (2003). [DOI] [PubMed] [Google Scholar]
  5. Eyre S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44, 1336–1340 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Vossenaar E. R. et al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25, 1106–1118 (2003). [DOI] [PubMed] [Google Scholar]
  7. Chang X. & Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 45, 183–196 (2006). [DOI] [PubMed] [Google Scholar]
  8. Nakashima K., Hagiwara T. & Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J Biol Chem 277, 49562–49568 (2002). [DOI] [PubMed] [Google Scholar]
  9. Bang S. Y. et al. Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study. Arthritis Res Ther. 12, R115 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Suzuki T. et al. PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. PLoS One 8, e61045 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cuthbert G. L. et al. Histone deimination antagonizes arginine methylation. Cell 118, 545–553 (2004). [DOI] [PubMed] [Google Scholar]
  12. Christophorou M. A. et al. Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature 507, 104–108 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wang Y. et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279–283 (2004). [DOI] [PubMed] [Google Scholar]
  14. Guo Q. & Fast W. Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem 286, 17069–17078 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yao H. et al. Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem 283, 20060–20068 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cui X. et al. The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One 8, e53791 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tanikawa C. et al. Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun 3, 676 (2012). [DOI] [PubMed] [Google Scholar]
  18. Schubert D. et al. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol 172, 4503–4509 (2004). [DOI] [PubMed] [Google Scholar]
  19. Tanaka-Watanabe Y. et al. B cells play a crucial role as antigen-presenting cells and collaborate with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritis. Clin Exp Immunol 155, 285–294 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Bockermann R. et al. Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase. Arthritis Res Ther 7, R1316–1324 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Iwanami K. et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 58, 754–763 (2008). [DOI] [PubMed] [Google Scholar]
  22. Willis V. C. et al. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol 186, 4396–4404 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rohrbach A. S. et al. PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis. Arthritis Res Ther 14, R104 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shelef M. A. et al. Peptidylarginine deiminase 4 contributes to tumor necrosis factor alpha induced inflammatory arthritis. Arthritis Rheumatol 66, 1482–1491 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gottenberg J. E. et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from ESPOIR cohort. Ann Rheum Dis 71, 1243–1248 (2012). [DOI] [PubMed] [Google Scholar]
  26. Presumey J. et al. Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Ann Rheum Dis 72, 1717–1724 (2013). [DOI] [PubMed] [Google Scholar]
  27. Pelletier M. et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115, 335–343 (2010). [DOI] [PubMed] [Google Scholar]
  28. Nauseef W. M. & Borregaard N. Neutrophils at work. Nat Immunol 15, 602–611 (2014). [DOI] [PubMed] [Google Scholar]
  29. Hurst S. M. et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14, 705–714 (2001). [DOI] [PubMed] [Google Scholar]
  30. Jones G. W. et al. Loss of CD4 + T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol 184, 2130–2139 (2010). [DOI] [PubMed] [Google Scholar]
  31. Tillack K. et al. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol 188, 3150–3159 (2012). [DOI] [PubMed] [Google Scholar]
  32. Li P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 207, 1853–1862 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pratesi F. et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis. 73, 1414–1422 (2014). [DOI] [PubMed] [Google Scholar]
  34. Khandpur R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5, 178ra40 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Romero V. et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med 5, 209ra150 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Marichal T. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 17, 996–1002 (2011). [DOI] [PubMed] [Google Scholar]
  37. Nakashima K. et al. PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun 4, 1836 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Matsumoto I. et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 48, 944–954 (2003). [DOI] [PubMed] [Google Scholar]
  39. Pettit A. R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159, 1689–1699 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Shoda H. et al. Detection of autoantibody to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory roles of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 13, R191 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep13041-s1.pdf (31.8KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES